<DOC>
	<DOCNO>NCT01072383</DOCNO>
	<brief_summary>This Phase II clinical study test safety efficacy BT061 psoriasis give repeated dos .</brief_summary>
	<brief_title>Safety Efficacy Multiple Doses BT061 Patients With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description>Patients enrol escalate dose level . Improvement PASI , physician 's global assessment itch score evaluate administration BT061 placebo . Safety data assess independent data safety monitor board ( DSMB ) .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female patient moderate , moderate severe severe chronic plaque psoriasis diagnose ≥ 12 month prior Screening . BSA ( Body surface area ) involvement &gt; 10 % 6 month . PASI ≥10 . Age ≥ 18 ≤ 75 year . Body mass index ( BMI ) 1830 kg/m2 body weight 50 130 kg . Erythrodermic , guttate palmar pustular psoriasis ( mixed form may admissible chronic plaque psoriasis clearly remain predominant diagnosis Treatment biological within less 30 day within less 5 halflives respective compound prior administration BT061/placebo . Serious local ( e.g . abscess ) systemic infection ( e.g . pneumonia , septicaemia ) within 3 month prior administration BT061 placebo . Presence history clinically significant immune deficiency autoimmune disease ( except psoriasis ) . Positive diagnosis acute chronic infection ( i.e . Hepatitis C Virus [ HCV ] , Hepatitis B Virus [ HBV ] , Human Immunodeficiency Virus [ HIV ] ) Screening visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>chronic plaque psoriasis</keyword>
	<keyword>psoriasis vulgaris</keyword>
	<keyword>autoimmune disease</keyword>
</DOC>